GT BIOPHARMA, INC. Cash Acquired from Acquisition
GT BIOPHARMA, INC. (GTBP) had Cash Acquired from Acquisition of $6.50 million as of 2023-01-04, per its 10-Q filed 2023-08-07.
Discontinued › Cash Flow › Cash
us-gaap:CashAcquiredFromAcquisition · last filed 2023-08-07
- 2023-01-04: Cash Acquired from Acquisition $6.50M.
| Period end | Cash Acquired from Acquisition |
|---|---|
| 2023-01-04 | $6.50M 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |